Blocking SHCBP1–PLK1 complex using targeted TFBG agent renders gastric cancer sensitive to HER2-directed therapy, providing additional combination therapy in HER2-positive patients with advanced gastric cancer. Here, PLK1 is linked to gastric cancer.